Initial Public Offering
Baird served as a co- manager on this offering.
AboutLantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) recently completed an initial public offering of 10,833,334 shares of common stock at a price of $6.00 per share, generating gross proceeds of approximately $65.0 million. The Company intends to use the net proceeds from the offering to reduce outstanding indebtedness and for working capital and other general corporate purposes.
Founded in 1956, Lantheus is a global leader in developing, manufacturing, selling and distributing innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s agents are routinely used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. Clinicians use Lantheus’ imaging agents and products across a range of imaging modalities, including echocardiography, nuclear imaging and magnetic resonance imaging, or MRI. The Company is headquartered in North Billerica, Massachusetts.
For additional information about this transaction, please contact:
- June 2015
- Lantheus Holdings, Inc.
- Target Location
- North America